Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Top Cited Papers
- 11 September 2014
- journal article
- clinical trial
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 28 (11), 983-992
- https://doi.org/10.1177/0269881114548296
Abstract
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.Keywords
This publication has 55 references indexed in Scilit:
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsJournal of Psychopharmacology, 2012
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinProceedings of the National Academy of Sciences, 2012
- Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteersDrug and Alcohol Dependence, 2011
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsPsychopharmacology, 2011
- Extended treatment of older cigarette smokersAddiction, 2009
- Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months laterJournal of Psychopharmacology, 2008
- Human hallucinogen research: guidelines for safetyJournal of Psychopharmacology, 2008
- Treatment of Alcoholism Using Psychedelic Drugs: A Review of the Program of ResearchJournal of Psychoactive Drugs, 1998
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991
- Self-efficacy and the stages of self-change of smokingCognitive Therapy and Research, 1985